![The Weekly Break Out Ep. 22: How the US hit Iran, and spooky space moves [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/250622_b2_takeoff_USAF-scaled-e1750776866152.jpg?#)
STAT+: Vaccine developer raises $45M for influenza drug trial
And more biotech news updates brought to you by The Readout.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Morning! Today, we talk about the readout of Compass Pathways’ psilocybin trial for major depressive disorder, see more vaccine concern and turnover at the FDA, and report from the American Diabetes Association.
The need-to-know this morning
- Nektar Therapeutics said its embattled immune drug rezpeg significantly improved skin clearance rates in patients with atopic dermatitis, achieving the goals of a Phase 2 study. The stock more than doubled in price in early trading.
Positive Compass therapy disappoints Wall Street
Compass Pathways said its Phase 3 trial of psilocybin for treatment-resistant depression met its primary endpoint, with a 3.6-point improvement on the MADRS scale over placebo — just above the company’s predefined threshold of success.
